Despite an overall dip in FDA approvals of new chemical and biologic entities, 2013 wasn't a bad year for innovator drugs. Jim Kling reports.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Two complementary approaches for intracellular delivery of exogenous enzymes
Scientific Reports Open Access 24 July 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Anonymous, US new drug approvals slip in 2013 vs prior year. Reuters, December 30, 2013. http://uk.reuters.com/article/2013/12/30/pharma-approvals-idUKL2N0K50J420131230/.
Blaiss, C. OBR Green 7, 11 (2013).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kling, J. Fresh from the biotech pipeline—2013. Nat Biotechnol 32, 121–124 (2014). https://doi.org/10.1038/nbt.2811
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2811
This article is cited by
-
Fresh from the biotech pipeline—2014
Nature Biotechnology (2015)
-
Two complementary approaches for intracellular delivery of exogenous enzymes
Scientific Reports (2015)
